S 247240
Alternative Names: S247240Latest Information Update: 05 Dec 2025
At a glance
- Originator Servier
- Class Neuroprotectants
- Mechanism of Action Large conductance calcium activated potassium channel modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fragile X syndrome
Most Recent Events
- 01 Sep 2025 Phase-I clinical trials in Fragile X syndrome in France (unspecified route) (Servier pipeline, September 2025)